← Human Trials & Peer-Reviewed Studies
Teriparatide and osseous regeneration in the oral cavity
Plain-language guide to PMID 20950166 (2010): placebo-controlled randomized controlled trial study of Teriparatide in 40 patients.
Key Facts
- PMID
- 20950166
- Journal
- The New England journal of medicine
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Bashutski JD et al. (8 authors)
- DOI
- 10.1056/NEJMoa1005361
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide in this randomized controlled trial publication.
Intermittent administration of teriparatide, a drug composed of the first 34 amino acids of parathyroid hormone, has anabolic effects on bone.
Although teriparatide has been evaluated for the treatment of osteoporosis and for the healing of fractures, clinical trials evaluating it for the treatment of osseous conditions of the oral cavity in humans are lacking.
Who Took Part
According to the abstract, 40 patients were involved.
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
The patients were followed for 1 year.
The primary outcome was a radiographic linear measurement of alveolar bone level.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.
A time span of 1 year appears in the methods.
Secondary outcomes included clinical variables, bone turnover markers in serum and oral fluid, systemic bone mineral density, and quality of life.
What Was Measured
Although teriparatide has been evaluated for the treatment of osteoporosis and for the healing of fractures, clinical trials evaluating it for the treatment of osseous conditions of the oral cavity in humans are lacking.
Topics PubMed links to this paper include Alkaline Phosphatase, Biomarkers, Bone Density Conservation Agents, Bone Regeneration, Chronic Disease, Combined Modality Therapy and Jaw.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Teriparatide in 40 patients over 1 year.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2010 (The New England journal of medicine), a journal based in United States.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.